Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

247 Results

Guidelines and Advice

Hepatitis B Virus Screening and Management for Patients Receiving Systemic Treatment

Status: Current

Sep 2022

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2022

Status: Current
ID: PET 2022-1

Jan 2023

Guidelines and Advice

Consensus Pathology Recommendations for Mesenchymal Tumours of Soft Tissue and Bone

Status: Current
Version: 1.0

Mar 2023

Guidelines and Advice

Fluoropyrimidine Treatment in Patients with Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Guidance for Clinicians

Status: Current
Version: 2

Updated

Sep 2025

Guidelines and Advice

Consensus-based organizational guideline for the planning and delivery of spine stereotactic body radiotherapy treatment in Ontario

Status: Current
ID: GL 21-6

Apr 2023

Guidelines and Advice

Cancer Care Ontario Thyroid Cancer Guideline: An Endorsement of the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer

Status: Current
ID: GL END 5-13
Version: N/A

Jun 2023

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines July to December 2022

Status: Current
ID: PET 2022-2

Jun 2023

Guidelines and Advice

Optimizing Ambulatory Systemic Treatment Models of Care

Status: Current
Version: 1

Jul 2023

Guidelines and Advice

An Endorsement of the 2022 NCCN Guideline on Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

Status: Current
ID: GL-END-C50-35

Aug 2023

Guidelines and Advice

Ontario Health (Cancer Care Ontario) Endorsement of ASCO Rapid Recommendation on 177Lutetium-Prostate-Specific Membrane Antigen-617 (PSMA-617) for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Status: Current
ID: GL-END 3-25

Nov 2023

Guidelines and Advice

Evidence from Primary Studies and Systematic Reviews and Recommendations from Clinical Practice Guidelines January to June 2023

Status: Current
ID: PET 2023-1

Nov 2023

Guidelines and Advice

Consensus Diagnostic and Prognostic Testing for Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic/Myeloproliferative Neoplasms: Recommendations Report - 2024

Status: Current
Version: 1.0

Jan 2024

Pages